SurfWax News Index  |  Track News  |  Save/Exchange Information |  About Us News and Articles on Base excision repair TRACON Pharmaceuticals Doses the First Patient in a Phase 1 Clinical Trial With Oral TRC102, An Inhibitor of Chemotherapy Resistance, in Combination With Alimta  Jun 18, 2008 TRC102 is a small molecule that has been shown to reverse resistance to the chemotherapy agent Alimta(r) in models of human cancer, by targeting the base excision repair pathway used to repair chemotherapy-induced DNA damage. Intravenous TRC102 is also being dosed to cancer patients in a Phase 1 clinical trial in combination with Temodar(r) being conducted at University Hospitals Case Medical Center. (Primezone Releases) Next Generation of Investigational Anti-Cancer Agents Unveiled at ASCO by AstraZeneca  Jun 4, 2007 PARP is an enzyme involved in Base Excision Repair which is a key pathway in the repair of DNA single-stranded breaks. Inhibiting this DNA repair mechanism, in tandem with a defective DNA repair gene like BRCA1 or BRCA2, is thought to lead to double-stranded DNA breaks that tumor cells are unable to repair, resulting in tumor cell death. (PR Newswire) Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population  Jun 26, 2006 The x-ray repair cross-complementing group 1 (XRCC1) gene is important in DNA base excision repair. We hypothesized that two common single nucleotide polymorphisms of XRCC1 (codons 194 Arg→Trp and 399 Arg→Gln) are related to the risk of NPC and interact with tobacco smoking. (BioMed Central) Back to Health News [ Terms Of Use | Privacy | About ] ©1998-2008 SurfWax, Inc. All rights reserved. Patents pending. Copyright SurfWax, Inc. 2008